Boron Biologicals Inc. (BBI) signed a partnership agreement withTechnology Management & Funding L.P. (TMF), which will help BBIsecure corporate partners to further the development of its proprietaryclass of boron compounds.The agreement calls for TMF of Princeton, N.J., to take an undisclosedequity position in BBI, a privately held company in Raleigh, N.C.BBI said the agreement with TMF should accelerate thecommercialization of its boron-based technology through alliances andadditional partnerships with major corporations. The company, formedin 1986, has a number of compounds in preclinical developmenttargeted for the treatment of cancer, osteoporosis, high cholesterol andinflammation.Last year BBI entered into a multiyear research contract and licensingagreement with Guerbet S.A., a French medical diagnostics company.They are jointly developing radiopaque contrast media imaging agents.

(c) 1997 American Health Consultants. All rights reserved.